Cure My Disease

Don't miss your cure!

 Log in / Sign up

Exercise may shield blood vessels from chemotherapy damage, study suggests

NCT ID NCT05223322

Disease control Sponsor: Medical College of Wisconsin Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time

Summary

This study looks at whether a 16-20 week exercise and coaching program can reduce inflammation and protect blood vessel health in Black and White women undergoing chemotherapy for breast cancer. Researchers will measure fitness, blood vessel function, and quality of life. The goal is to understand how exercise might help prevent long-term heart problems caused by cancer treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a 16-20 week exercise and coaching program called Taking Charge during Treatment (TCT)
What this could lead to
If successful, this could show that a structured exercise program helps protect blood vessels from chemotherapy damage, potentially reducing long-term heart risks in breast cancer survivors.
What could go wrong
This is an early-stage observational study with only 80 participants, so results may not apply to all groups. The exercise program may be difficult for some to complete, and the study does not test a drug or cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2022

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 100 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult (≥ 18 years) assigned female sex at birth * Diagnosed with invasive non-metastatic breast cancer * Receiving neo-adjuvant CTx (or adjuvant CTx and undergoing breast conserving surgery) that includes anthracyclines (such as DOX) and/or targeted anti-Her2 therapy * Able to safely participate in moderate exercise and strength training based on MD approval * Willing to complete all study activities * Self-identifies as Black/African American or non-Hispanic White Exclusion Criteria: * Unintentional weight loss \> 10% in the past 6 months * Current pregnant and lactating patients. Must have completed lactation prior to study start * Metastatic disease * Diagnosed cardiovascular disease as evidenced by cardiomyopathy (reduced regional or global LV contractility), diastolic dysfunction grade 2 or above, symptomatic coronary - artery disease, ejection fraction below 50% * History of prior chemotherapy or targeted H2N Treatment received less than 3 years ago * Non-English speaking

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm invasive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer

Contacts and locations

Locations

  • Medical College of Wisconsin

    Wauwatosa, Wisconsin, 53226, United States

  • University of Illinois Chicago

    Chicago, Illinois, 60607, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.